| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Akero Therapeutics Inc (NASDAQ: AKRO)
AKRO Technical Analysis
5
| As on 9th Jun 2023 AKRO STOCK Price closed @ 52.49 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 19.13 & Strong Buy for SHORT-TERM with Stoploss of 19.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AKROSTOCK Price
| Open | 52.21 | Change | Price | % |
| High | 53.73 | 1 Day | 0.83 | 1.61 |
| Low | 51.97 | 1 Week | 7.91 | 17.74 |
| Close | 52.49 | 1 Month | 8.86 | 20.31 |
| Volume | 431000 | 1 Year | 31.07 | 145.05 |
| 52 Week High 54.80 | 52 Week Low 8.00 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| AKRO Daily Charts |
AKRO Intraday Charts |
Whats New @ Bazaartrend |
AKRO Free Analysis |
|
|
AKRO Important Levels Intraday
| RESISTANCE | 55.88 |
| RESISTANCE | 54.79 |
| RESISTANCE | 54.12 |
| RESISTANCE | 53.45 |
| SUPPORT | 51.53 |
| SUPPORT | 50.86 |
| SUPPORT | 50.19 |
| SUPPORT | 49.10 |
AKRO Forecast May 2024
| 4th UP Forecast | 65.27 |
| 3rd UP Forecast | 61.17 |
| 2nd UP Forecast | 58.64 |
| 1st UP Forecast | 56.1 |
| 1st DOWN Forecast | 48.88 |
| 2nd DOWN Forecast | 46.34 |
| 3rd DOWN Forecast | 43.81 |
| 4th DOWN Forecast | 39.71 |
AKRO Weekly Forecast
| 4th UP Forecast | 56.75 |
| 3rd UP Forecast | 55.38 |
| 2nd UP Forecast | 54.54 |
| 1st UP Forecast | 53.69 |
| 1st DOWN Forecast | 51.29 |
| 2nd DOWN Forecast | 50.44 |
| 3rd DOWN Forecast | 49.60 |
| 4th DOWN Forecast | 48.23 |
AKRO Forecast2024
| 4th UP Forecast | 143.75 |
| 3rd UP Forecast | 114.48 |
| 2nd UP Forecast | 96.39 |
| 1st UP Forecast | 78.3 |
| 1st DOWN Forecast | 26.68 |
| 2nd DOWN Forecast | 8.59 |
| 3rd DOWN Forecast | -9.5 |
| 4th DOWN Forecast | -38.77 |
Akero Therapeutics Inc ( NASDAQ USA Symbol : AKRO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AKRO Business Profile
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service